Isoflavones inhibit intestinal epithelial cell proliferation and induce apoptosis in vitro by Booth, C et al.
The incidence of intestinal cancer is high in Western populations
but is relatively uncommon in Asia and Africa (Boyle et al, 1985).
It is thought that this variation in incidence is strongly influenced
by diet (Armstrong and Doll, 1975; Adlercreutz, 1990) and it is
estimated that about 32% of deaths by all cancers, and 70% of
deaths from colorectal cancer, could be prevented by a change in
diet (Willet, 1995). There is also evidence to suggest that a high
intake of soya-based foods (as in populations of Southeast Asia)
could contribute to a reduced incidence of mammary (Lee et al,
1995) and prostate (Severson et al 1989) cancer.
Soya beans are an abundant source of the isoflavones genistein,
daidzein and glyceitin (Wang and Murphy, 1994). These diphenol
molecules are structurally similar to the steroidal oestrogens and
thus, have been termed phyto-oestrogens. Due to this similarity,
attention has focused on the role of phyto-oestrogens in preventing
both hormonally mediated (particularly breast) and hormonally
independent cancers. Soya metabolites may reduce the risk of
colon cancers (Messina et al, 1994). Genistein in particular
possesses several anti-tumorigenic activities in vitro, including
inhibition of angiogenesis (Fotsis et al, 1993), topoisomerase
(Okura et al, 1988) and tyrosine kinase (Ogawara et al, 1989)
activity, in addition to having antioxidant properties (Wei et al,
1993). Experiments using colon cancer cell lines have shown that
genistein, and the related isoflavone biochanin A, can inhibit cell
proliferation and induce apoptosis (Yanagihara et al, 1993; Kuo,
1996), again implying protective effects.
No data are available to demonstrate the effects of isoflavones
on normal intestinal cell lines. In this study we aimed to investi-
gate the proliferative and apoptotic effects of genistein in vitro on
normal intestinal epithelial cells and compare these to the effects
on malignant cell lines. We also aimed to examine the effects of
some novel isoflavones, which have been synthesized primarily as
specific tyrosine kinase inhibitors, upon the same cell lines. The
effects of these isoflavones are compared with the effects of
oestradiol, the anti-oestrogen tamoxifen, and the specific tyrosine
kinase inhibitor, tyrphostin.
MATERIALS AND METHODS
Cell culture methods
IEC18 and IEC6 cells, related clones isolated from normal
neonatal rat small intestine, were originally obtained from A
Quaroni (Quaroni and May, 1980). In all assays these lines were
used below passage 20. SW620 and HT29 human colon adeno-
carcinoma lines were obtained from the English Tissue Culture
Collection (ETCC, Porton Down, Wilts, UK). All cells were main-
tained and passaged in Dulbecco’s modified Eagles medium
(DMEM) (GibcoBRL, Paisley, UK) containing 5% fetal calf
serum (FCS) (Sigma, Poole, UK), 0.25 U ml–1 insulin (Hypurin,
Fisons, Loughborough, UK), 100 U ml–1 penicillin and 30 mg ml–1
streptomycin (all Sigma, Poole, UK). Charcoal-stripped FCS,
phenol red free DMEM, genistein, biochanin A, oestradiol, tamox-
ifen and tyrphostin 25 were all purchased from Sigma. Novel
isoflavones were synthesized and purified within the Paterson
Institute (see below).
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Isoflavone synthesis
Synthetic intermediates were purchased from Aldrich, Kodak or
Lancaster Synthesis. NMR spectra were determined on either a
Hitachi Perkin-Elmer R-600 (at 60 MHz) or a Bruker AC300 (at
300 MHz) NMR spectrometer in CDCl3 (unless otherwise stated)
and are expressed in d values relative to tetramethylsilane. Infra-
red spectra were recorded on a Mattson 1000 FTIR spectrometer
and are expressed in cm–1. Melting points are uncorrected.
Microanalyses were carried out by the Micro-analytical labora-
tory, Department of Chemistry, University of Manchester, UK.
Electron impact mass spectra were determined using a VG Trio 2
mass spectrometer at an ionization energy of 70 eV.
5,7-Dihydroxy-3-(2-methoxyphenyl)-4H-1-benzopyran-4-
one (compound 1)
To a solution of 2-methoxybenzyl-2,4,6-trihydroxyphenyl ketone
(1.5 g, 5.47 mmol) in dimethyl formamide (15 ml) under argon
was added BF3 etherate (2.7 ml, 3.12 g, 21.9 mmol) followed by
methanesulphonyl chloride (1.26 ml, 1.86 g, 16.3 mmol). The
mixture was heated on a steam bath in an open flask for 90 min,
cooled, poured into water (60 ml) and extracted with
dichloromethane (3 ´ 20 ml). The organic extracts were washed
with water (2 ´ 20 ml), brine (20 ml) and dried (MgSO4). After
evaporation of the solvent the resultant yellow gum solidified on
trituration with ether and dichloromethane. Crystallization from
aqueous ethanol gave a white powder (1.23 g, 79%) mp
192–193°C (lit mp 195–197°C (16). IR (KBr): 3309 (OH); 1650
(C=O); 1621 (C=C). NMR: 3.70 (3 H, s, OMe); 6.22, 6.40 (2 H, 2
d, J = 2 Hz, 6-H, 8-H); 6.90–7.52 (4 H, m, ArH); 7.89 (1 H, s,
exchanges with D2O, 5-OH); 8.20 (1 H, s, C=C-H); 9.91(1 H, bs,
exchanges with D2O, 7-OH). M+, 284 (100%); 253(M – OMe,
91%).
5,7-Dihydroxy-2-ethoxycarbonyl-3-(2-methoxyphenyl)-
4H-1-benzopyran-4-one (compound 2)
To a stirred solution of 2-methoxybenzyl-2,4,6-trihydroxyphenyl
ketone (1 g, 3.65 mmol) in pyridine (6.8 ml) at 0°C was added
ethyl oxalyl chloride (1.63 ml, 1.99 g, 14.6 mmol). After 24 h the
reaction mixture was poured into water (50 ml) and extracted with
chloroform (3 ´ 15 ml). The combined organic extracts were
washed with 2 M hychochloric acid (HCl) (3 ´ 10 ml), dried
(MgSO4) and the solvent evaporated to give the title ester (2) as a
yellow solid (1.04 g, 80%) from aqueous methanol mp 151–2°C
(lit mp 154–6°C (16). M+, 356 (69%); 325 (M – OMe, 81); 283
(M – EtCO2, 100).
3-Methoxybenzyl-2,4,6-trihydroxyphenyl ketone
(compound 3)
A stream of dry HCl gas was passed through a solution of
phloroglucinol (10 g, 79.3 mmol), 3-methoxyphenylacetonitrile
(10 g, 68 mmol) and zinc chloride (4 g) in diethyl ether at 0°C for
4 h. After 2 days at 0°C, 200 ml ether was added to precipitate a
yellow–orange oil. The ether was decanted and the residual oil
heated under reflux in 1% aqueous sulphuric acid (500 ml) for 1 h.
On cooling the ketone precipitated as colourless crystals
(13.98 g, 75%), mp 165–166°C (from aqueous methanol). (Found:
C, 65.9; H, 5.1 C15H14O5 requires C, 65.7; H, 5.1%). IR (KBr):
3272 (OH); 1629 (C = O). NMR: 3.74 (3 H, s, OMe); 4.32 (2 H, s,
ArCH2); 5.82 (2 H, s, 3-H, 5-H); 6.82 (3 H, bs, 2-H, 3-H, 4-H);
7.16 (1 H, d, J = 7 Hz, 5-H); 10.40, 12.20 (3 H, 2bs, exchange with
D2O,  3 ´ OH).
5,7-Dihydroxy-3-(3-methoxyphenyl)-4H-1-benzopyran-4-
one (compound 4)
From ketone (3) (1 g, 3.65 mmol) by the method described above
for isoflavone (1) was obtained the title compound (4) as white
crystals (0.86 g, 83%) mp 190–2°C (from aqueous ethanol).
(Found: C, 67.65; H, 4.2. C16H12O5 requires C, 67.6; H, 4.3%). IR
(KBr): 3199 (OH); 1653 (C=O). NMR: 3.74 (3 H, s, OMe); 6.20,
6.32 (2 H, 2 d, J = 2 Hz, 6-H, 8-H); 6.88–7.50 (4 H, m, 2,4,5,
6-Hs); 7.83 (1 H, s, exchanges with D2O, 5-OH); 8.37 (1 H, s,
2-H); 9.80–9.95 (1 H, bs, exchanges with D2O, 7-OH). M+,
284 (100%).
5,7-Dihydroxy-3-(3-hydroxyphenyl)-4H-1-benzopyran-4-
one (compound 5)
A solution of methyl ether (4) (200 mg, 0.7 mmol) in hydrobromic
acid (2.3 ml, d = 1.46) and acetic acid (2.3 ml) was heated at
140–150°C for 3 h. After cooling, water (5 ml) was added and the
product was filtered off as a fawn solid (180 mg, 95%) mp 242°C
(lit mp 203–205°C, (17). (Found: C, 63.0; H, 4.2. C15H10O5. H2O
requires C, 62.5; H, 4.2%). NMR (acetone-d6): 6.40 (1 H, d, J =
2 Hz, 6-H); 6.53 (1 H, d, J = 2 Hz, 8-H); 6.97 (1 H, dd, J = 8 Hz,
J = 2 Hz, 4-H); 7.14 (1 H, bd, J = 8 Hz, 6-H); 7.23 (1 H, dd, J =
3 Hz, J = 2 Hz, 2-H); 7.36 (1 H, t, J = 8 Hz, 5-H); 8.30 (1 H, s,
2-H), 9.70–10.00 (2 H, bs, 3-OH, 7-OH); 13.07 (1 H, s, 5-OH).
M+, 270 (100%).
3,4,5-Trimethoxybenzyl-2,4,6-trihydroxyphenyl ketone
(compound 6)
By the method described for ketone (3) from 3,4,5-
trimethoxyphenylacetonitrile (5 g, 23.2 mmol), phloroglucinol
(5 g, 39.7 mmol) and zinc chloride (4 g) in ether (75 ml) the title
ketone (6) was obtained as colourless crystals (5.05 g, 63%) mp
197–198°C (from aqueous methanol). (Found: C, 61.2; H, 5.6.
C17H18O7 requires C, 61.1; H, 5.4%). IR (KBr): 3411, 3280 (OH);
1640 (C=O). NMR (DMSO-d6): 3.30 (1 H, bs, exchanges with
D2O, OH); 3.75, 3.83 (9 H, 2 s, 3 ´ OMe); 4.28 (2 H, s, CH2); 5.84
(2 H, s, 3,5-Hs); 6.54 (2 H, s, 2,6-Hs); 8.60 (2 H, bs, exchanges
with D2O, 2 ´ OH). M+, 334 (33%); 153 (M – 3,4,5-
triMeOphenylCH2, 100%).
5,7-Dihydroxy-3-(3,4,5-trimethoxyphenyl)-4H-1-
benzopyran-4-one (compound 7)
By the method described for isoflavone (1) the title heterocycle (7)
was prepared from ketone (6) (0.6 g, 1.8 mmol), boron trifluoride
etherate (0.9 ml) and methanesulphonyl chloride (0.42 ml) as a
white crystalline solid from aqueous ethanol (0.83 g, 81%) mp
224–226°C (lit mp 228°C. (Found: C, 62.2; H, 4.6. Calculated for
C18H16O7 C, 62.3; H, 4.7%). IR (KBr): 3351 (OH); 1670 (C=O).
NMR: 3.68 (3 H, s, OMe); 3.78 (6 H, s, 2 ´ OMe); 6.20, 6.39 (2 H,
2 d, J = 2 Hz, 6, 8-Hs); 6.86 (2 H, s, 2, 6-Hs); 7.83 (1 H, s,
exchanges with D2O, 5-OH); 8.41 (1 H, s, 2-H); 9.80–9.95 (1 H,
bs, exchanges with D2O, 7-OH). M+, 344 (100%); 329 (M-CH3,
32).1552 C Booth et al
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5-Hydroxy-7-methoxy-3-(3-methoxyphenyl)-4H-1-
benzopyran-4-one (compound 8)
A mixture of isoflavone 5 (200 mg, 0.7 mmol), dimethyl sulphate
(1.41 mmol) and sodium hydroxide (0.062 g) in water (2 ml) was
heated at 70–80°C for 1 h. The solvent was decanted and
remaining solid was dried and crystallized from ethanol as white
crystals (150 mg, 71%) mp 99–100°C. (Found: C, 68.4; H, 4.5.
C17H14O5 requires C, 68.5; H, 4.7%). M+, 298 (100%).
5,7-Dihydroxy-2-ethoxycarbonyl-3-(3,4,5,-
methoxyphenyl)-4H-1-benzopyran-4-one (compound 9)
To a stirred solution of ketone 6 (0.9 g, 2.7 mmol) in pyridine
(5 ml) at 0°C was added ethyl oxalyl chloride (1.2 ml, 10.7 mmol).
After stirring overnight the mixture was poured into cold water
(20 ml) and extracted with chloroform (4 ´ 5 ml), water (5 ml) and
dried over MgSO4. Evaporation afforded a froth which, after tritu-
ration with ether and crystallization from aqueous ethanol, yielded
the title ketone (9) (0.99 g, 85%) mp 199–200°C. (Found: C, 60.5;
H, 4.8. C21H20O9 requires C, 60.6; H, 4.8%). IR (KBr): 3288 (OH);
1725 (C=O, ester); 1660 (C=O, ketone). NMR: 1.01 (3 h, t, J=
7 Hz, CH3CH2); 2.75, 2.79 (9 H, 2 s, 3 ´ OMe) 4.18 (2 H, q,
J=7 Hz CH3CH2); 6.32, 6.45 (2 H, 2 d, J 2 Hz, ArHs ortho to
OHs); 6.62 (2 H, s, ArHs ortho to OMe). M+, 416 (100%); 401
(M-OMe, 25%).
Standard assay procedure
For both growth stimulation and inhibition assays 2 ´ 104 IEC6 (or
IEC18) cells per well were plated out in 24-well culture plates
(Costar) containing 0.2% (stimulatory assay) or 2% FCS
(inhibitory assay), in 1 ml of the above media. Two per cent FCS
will maintain significant cell growth, whereas 0.2% permits cell
survival with minimal proliferation. Adenocarcinoma cell lines
were all plated out in 2% FCS to permit optimal initial attachment.
The assay was conducted 24 h after plating (t = 0) when all the
cells were attached to the plates. Cells were then change into the
appropriate medium with or without the freshly dissolved test
substance (isoflavone). Plates were fed by addition of 0.5 ml of the
appropriate media on day 3, and harvested as described below.
For assays in non-oestrogenic conditions, cells grown in stan-
dard 5% FCS DMEM were trypsinized, stopped in media
containing normal serum and then washed in phenol red free
media (PRFM). Cells were then plated out as above in PRFM
containing either 2 or 0.2% charcoal-stripped FCS.
Each isoflavone was dissolved in dimethylsulphoxide (DMSO)
to 50 mg ml–1 and then diluted to the highest concentration
(50 mg ml–1) in media. This was sterile filtered through a 0.2 mm
membrane and diluted as necessary. Slow dilution with constant
vortexing maintained the isoflavones in solution. Freshly
dissolved isoflavones were used for each feed because activity was
found to be reduced on storage (data not shown).
Growth curves were obtained by fixing the plates at the relevant
time points with 70% ethanol and after drying, staining with 0.1%
crystal violet for 5 min. After rinsing with water and air-drying,
the dye was extracted from the cells using 2% sodium deoxy-
cholate and the staining intensity measured by absorption at
595 nm. Using this technique we have previously shown that
absorption is an accurate index of cell number between 104 and
2.5 ´ 105 cells per well. Outside this range responses are detectable
but not linear (Potten et al, 1993).
Tyrosine kinase assay
Stock solutions (200 ml) of the mouse leukaemic cell line P388
were prepared. Cells were collected during exponential growth
(5  ´ 105 cells ml–1), washed once in cold phosphate-buffered saline
(PBS) and then vortexed in cold lysis buffer (10 mM HEPES,
pH 7.6, 10 mM sodium chloride (NaCl), 2 mM EDTA, 1 mM phenyl-
methyl sulphonyl fluoride (PMSF), 10 mg ml–1 aprotenin and
10 mg ml–1 leupeptin). All subsequent steps were carried out at
4°C. The lysates were homogenized in a Dounce homogenizer and
nuclei and cell debris were removed by centrifugation (10 min at
1000 g). Membrane extracts were then pelleted using a Beckman
(USA) L8-M ultracentrifuge (30 min at 1 ´ 105 g ) and then were
resuspended in HNG buffer (50 mM HEPES, pH 7.6, 125 mM
NaCl and 10% (v/v) glycerol). Protein concentration was deter-
mined using Biorad protein assay with a bovine serum/albumin
(BSA) standard curve. Solutions were divided into 35 ml aliquots
and immediately frozen at –80°C.
Assay of PTK inhibition was based on measurement of the
phosphorylation of an exogenous synthetic peptide, RR-SRC
(Casnellie et al, 1982). This peptide was based on the autophos-
phorylation site of pp60v-src, with two additional arginine residues
at one end in order to facilitate attachment to phosphocellulose
paper. Control assays with the RR-SRC peptide were used to
measure non-specific phosphorylation.
Each drug was initially screened at high concentration (5 mM).
If inhibition was observed then a range of concentrations were
used to define an IC50 (the drug concentration necessary to achieve
50% inhibition of phosphorylation). All drugs were dissolved in
DMSO and all experiments were performed in duplicate. Each
assay consisted of 10 ml standard substrate solution (1 mM RR-
SRC peptide substrate, 60 mM HEPES, 20 mM magnesium
chloride (MgCl2), 40 mM EDTA, 200 mM dithiothreitol (DTT),
50 mg ml–1 BSA, 0.3% (v/v) Nonidet P-40, 140 mM sodium ortho-
vanadate and 120 mM ATP) or control solution (as substrate solu-
tion but without RR-SRC peptide), 0.5 ml [g-32P]-ATP, 0.5 ml PBS,
7 ml membrane solution (as prepared above, diluted to optimum
concentration with PBS) and 2 ml DMSO (with or without
inhibitor). Assay tubes were incubated at 30°C for 30 min, after
which the reaction was terminated by addition of 20 ml ice-cold
10% TCA. After 10 min on ice membranes were precipitated by
microcentrifugation, and 20 ml of supernatant per assay was
spotted on individual phosphocellular discs, washed twice in 1%
acetic acid and twice in water to remove non-incorporated [g-32P],
before liquid scintillation counting. Three further vials, each
containing 0.09 ml [g-32P]-ATP (2 ml of substrate solution mixed
with [g-32P]-ATP and PBS) in 5 ml scintillation fluid were
measured in order to calibrate the radioactivity of the [g-32P] for
that experiment.
Apoptosis
Apoptotic cells were identified by staining with Hoescht 33258.
Briefly, 25 ml of trypsinized cells in serum-free media (106 ml–1)
were allowed to attach to each well of a poly-L-lysine coated
multi-well glass slide (contained in a Petri dish) for 15 min.
Fifteen millilitres of 2% FCS containing DMEM was then added
to the Petri dish, thereby covering the slide. After 24 h the medium
was replaced with fresh medium containing the isoflavone to be
assayed. After 3 days, slides were fixed for 10 min in 4% formal
saline, washed in PBS, permeabilized for 5 min in 1% Nonidet-
P40 in PBS, and stained for 20 min in 10 mg ml–1 Hoescht 33258.RESULTS
Effect of genistein on normal intestinal epithelial cells
Figure 1 shows that concentrations above 1 mg ml–1 genistein
dramatically inhibited cell proliferation in 2% FCS in the untrans-
formed rat small intestinal cell line, IEC18. The same result was
true for the related IEC6 cell line (data not shown). However,
it can also be seen from Figure 1 that lower doses of genistein
(< 1 mg ml–1), appeared to drive a slight stimulation in cell growth
(more pronounced when control growth was minimal, i.e. 0.2%
FCS or growth in oestrogen-free conditions (data not shown). At
high genistein concentrations (25 mg ml–1) inhibition of cell
growth was accompanied by cell death via apoptosis (Figure 2
A–C).
Genistein and tamoxifen are more potent inhibitors of
intestinal cell proliferation than their natural relatives
Biochanin A also inhibited IEC18 cell growth, although this
isoflavone was less potent in its inhibitory activity than genistein
(Figure 3). Oestradiol and tyrphostin possessed similar activity
to biochanin A, whereas the anti-oestrogen tamoxifen was an
equally, if not more potent, inhibitor than genistein. Stimulatory
effects could not be induced with any of these novel isoflavones in
this dose range (0.1–25 mg ml–1). Experiments using much lower
concentrations of estradiol, indicated a slight growth stimulation
at 10–9 (0.27 ng ml–1) to 10–11 M (data not shown).
This activity profile was similar in the SW620 tumour cell line
(Figure 4A), although genistein did not show any stimulatory
effect at low concentrations. The induction of apoptosis in HT29
cells by genistein is illustrated in Figure 2 D,E. Interestingly, in the
HT29s, tamoxifen exhibited a much more marked inhibitory effect
(Figure 4B) whereas oestradiol was only a weak growth inhibitor.
Isoflavone effects on gut epithelial cells 1553
British Journal of Cancer (1999) 80(10), 1550–1557 © 1999 Cancer Research Campaign
1.5
1.25
1
0.75
0.5
0.25
0
R
e
l
a
t
i
v
e
 
c
e
l
l
 
n
u
m
b
e
r
 
(
C
V
 
A
B
S
)
50 25 10 5 2.5 1 0.5 0.1 0.05
Concentration mg ml–1 (log)
Figure 1 Dilution curve for genistein when applied to IEC18 cells growing
in 2% FCS, presented on a log scale. The cell numbers (as measured by
crystal violet dye binding) after 5 days exposure, relative to the untreated
control, are shown. Genistein can be seen to reduce cell number by up
to 80%
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Figure 2 (A–C) Hoescht labelling of IEC18 cells growing in 2% FCS and
treated with 25 mg ml–1 genistein. Control cells (A) growing in culture and
displaying several mitotic figures gradually begin to apoptose within 24 h (B)
until after 72 h (C) most cells have died and detached from the substrata.
HT29 cells behave similarly: control (D), 72 h (E). IEC18 cells treated for 72 h
with isoflavone 4 again appeared to die via apoptosis (F)
1.25
1
0.75
0.5
0.25
0
R
e
l
a
t
i
v
e
 
c
e
l
l
 
n
u
m
b
e
r
 
(
C
V
 
A
B
S
)
50 25 10 5 2.5 1 0.5 0.1 0.05
Concentration mg ml–1 (log)
Genistein
Oestradiol
Tamoxifen
Tyrphostin 25
Biochanin
Figure 3 Genistein and tamoxifen were potent inhibitors of IEC18 cell
proliferation. Oestradiol, tyrphostin 25 and biochanin were less inhibitory, all
having similar potencies1554 C Booth et al
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Genistein is a more potent inhibitor of intestinal cell
proliferation than a range of novel isoflavones
A number of novel isoflavones were synthesized in order to try
to identify potentially more potent inhibitors of cell growth
(Figure 5). Their effects were assessed on both normal and trans-
formed cell lines and compared to their natural counterparts. It can
be seen from Figure 6 that all the novel isoflavones inhibited cell
proliferation. The molecular weights of these compounds are all
very similar, and hence results are presented as mg ml–1 compar-
isons. Only isoflavone 4 approached the potency of genistein (and
also killed the cells by apoptosis) (Figures 6 and 2). The relative
IEC18 cellularities after exposure to 25 mg ml–1 of isoflavones can
be seen clearly in Figure 7. The same relative activities displayed
in the normal intestinal epithelial cell lines (IEC6, IEC18) were
also displayed in the SW620 and HT29 adenocarcinoma cell lines
(Figure 8).
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Figure 4 Effect of genistein, oestradiol and tamoxifen on two carcinoma cell lines. Genistein exhibited similar inhibitory activity on both cell lines (SW620 cells
(A) appeared slightly more sensitive). Oestradiol was less potent and but again appeared to exhibit more inhibition on the SW620 cells. Conversely, tamoxifen
was much more effective on the HT29 cells, (B) with marked sensitivity (75% fewer cells) still evident in this cell line at 1 mg ml–1, a concentration at which only
25% fewer SW620 cells were present
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In order to test whether this result might be due to tyrosine
kinase inhibition the effects of the synthetic isoflavones on the
activity of this enzyme were also examined. It can be seen that a
similar potency spectrum is apparent (as compared to IEC18
growth inhibition) for all the isoflavones except 5, indicating this
might contribute to the mechanism of action of these isoflavones
(Figure 9). A correlation of cellularity with inhibition of PTK
activity showed a correlation coefficient of 0.68, although this did
not attain significance (P = 0.94, Spearman test). Further work on
other analogues is necessary to fully evaluate the inter-relationship
of these parameters.
DISCUSSION
We have demonstrated that the isoflavones biochanin A, genistein
and the synthetic analogues have an inhibitory effect on both rat
intestinal (‘normal’) and human colon adenocarcinoma cell lines.
Unfortunately, same species comparisons are not possible as
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Figure 6 Dilution curves for the synthetic isoflavones (cell numbers present after 5-day exposures). IEC18 cells were more sensitive to inhibition by genistein
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normal human or rat tumour cell lines are not available. Hence, the
best available alternatives were used – cell lines that have been
widely used by many groups to successfully detect normal vs
tumour differences in the intestinal epithelium. We have also
recently tested the effects of these compounds on a novel primary
culture model of mouse colonic epithelium (Booth et al, 1995), as
an additional control, with the same spectrum of activities across
the isoflavones as observed in the cell lines.
The naturally occurring genistein was found to have the most
potent dose-dependent effect, even compared to synthetic
isoflavones synthesized particularly for their possible growth
inhibitory effects. The isoflavones 1, 2, 4, 5, 7, 9 and the ketone 3
(the synthetic precursor of 4 and 5) were synthesized as structural
analogues of the naturally occurring genistein and biochanin A.
Genistein is a known PTK inhibitor (Peterli et al, 1992) and
biochanin A is a non-specific inhibitor of protein kinases (Wang et
al, 1997). The oxygenation pattern on the phenyl ring was altered
to discover whether simple isomeric alteration (1, 2, 4, 5) or extra
methoxylation (7, 9) would affect the biochemistry of the
isoflavones. It appears from these studies that these structural
alterations do not lead to an increase in the efficacy of isoflavone-
induced cell death. No structure–function relationship could be
detected.
Although the exact mechanisms of action of the isoflavones
have yet to be fully elucidated, induction of apoptosis may be
partly responsible. Induction of apoptosis by genistein has pre-
viously been demonstrated in human cancer cells of gastro-
intestinal origin and it was suggested that inhibition of cell growth
was via this process (Yanagihara et al, 1993). We have also shown
that genistein (together with biochanin A and the other novel
isoflavones) caused apoptosis in both the small intestinal and
colonic cell lines, although this has not been quantitated. In addi-
tion to inducing apoptosis, genistein and the other novel
isoflavones assayed exhibited tyrosine kinase inhibitory activity.
Although this is a lysate rather than a cellular assay the result is
consistent with other observations that have previously demon-
strated genistein to be an effective epidermal growth factor
receptor-associated PTK inhibitor (Akiyama et al, 1987), presum-
ably blocking the cell proliferation signalling process. Indeed, in
our study addition of the specific tyrosine kinase inhibitor
tyrphostin to cells originating from both the small intestine and
colon inhibited cell growth. An increase in cell proliferation is
believed to be an important factor in the development of some
human tumours and therefore inhibition of PTK activity has been
put forward as a target for cancer therapy (Powis and Kozikowski,
1991). For example, in vivo data suggest that treatment with an
epidermal growth factor-specific PTK inhibitor can inhibit
mammary and oesophageal tumour growth (Toi et al, 1990).
However, it is unlikely that PTK inhibition is solely responsible
for the growth inhibition observed in this study, since isoflavone 5
was shown to have the highest PTK inhibitory effect, but was a
less potent growth inhibitor.
The only data available regarding possibly protective levels of
genistein in humans found that the peak serum concentrations in
experimental subjects consuming soy milk, containing 50 mg
genistein daily, reached 0.2 mg ml–1 (Xu et al, 1994). It has also
been estimated that in populations consuming soy-rich diets,
serum genistein is unlikely to rise above 0.85–1.14 mg ml–1
(Barnes et al, 1995). Our data suggest that genistein levels above
1 mg ml–1 have an inhibitory effect upon intestinal cells, but lower
levels either have no effect or stimulate cell growth. Although it is
difficult to extrapolate in vitro data to the in vivo situation, the
available data suggest that it may be difficult to obtain sufficient
genistein to obtain beneficial biological effects from diet alone.
However, the effect of long-term persistent exposure to low doses
of genistein and the different sensitivities of the cells in intestinal
epithelial cell hierarchy (particularly the sensitivity of the stem
cells) remains unknown.
Oestradiol and tamoxifen inhibited all the cell lines. Although
the intestine is a non-target organ for oestrogen, functional
oestrogen receptors have been located on non-transformed
intestinal cells (Thomas et al, 1993). The results of previous
studies examining the effect of oestradiol upon cells of the colon
have been disparate. Oestradiol has been shown to both inhibit and
increase cell proliferation (Xu and Thomas, 1994; Singh et al,
1997). In humans, the use of oestrogenic hormone replacement
therapy is associated with a decreased colon cancer risk (Potter
et al, 1996; Kampman et al, 1997) suggesting that oestrogen may
exert a protective effect. Our data support the inhibitory effect of
oestradiol upon intestinal cells and suggest such protection may
occur via induction of apoptosis. Phyto-oestrogens have a struc-
tural similarity to oestradiol and have been shown to have
oestrogen antagonist (Pagliacci et al, 1994) and agonist (Welshons
et al, 1987; McMichael-Phillips et al, 1996) activities, which is
probably a dose-dependent effect (Zava et al, 1997). In breast
cancer cells genistein can compete with oestradiol for oestrogen
receptor binding sites (Martin et al, 1978) and the ability to process
nuclear receptors and increase cell growth is analogous to the
biological actions of oestradiol. It is possible that the inhibitory
and stimulatory effects of genistein and the novel isoflavones
assayed upon intestinal cells are due in part to these dose-
dependent oestrogenic activities. Details of the effects of these
compounds on oestrogen receptor binding affinity remain to be
determined.
Consumption of isoflavone-rich foods, such as soya products,
have been linked with a decrease in breast cancer risk (Lee et al,
1995). Furthermore, men with a low risk of prostate cancer have a
higher urinary excretion of phyto-oestrogens than those popula-
tions with an increased cancer risk (Adlercreutz et al, 1993).
Urinary phyto-oestrogen levels are also decreased in women with
breast cancer (Ingram et al, 1997). Soyabean diets and individual
isoflavones have also been shown to offer protection against
mammary tumour development in animal models of cancer (Troll
et al, 1980; Lamartiniere et al, 1995) and the related, naturally
occurring flavone, quercetin, has been shown to decrease the
growth of gastric cancer cells (Yoshida et al, 1990). It is likely that
several anticancer mechanisms are involved in the protection
offered by dietary isoflavones, examples that we have shown here
are that apoptosis, oestrogenicity and tyrosine kinase inhibition
may play a role. Genistein has also been shown to have other
biological activities which may inhibit tumour formation and
growth, including inhibition of topoisomerase (Okura et al, 1988)
and angiogenesis (Fotsis et al, 1993) and induction of cell differen-
tiation (Constantinou et al, 1990). However, all of these may be a
direct consequence of tyrosine kinase inhibition.
Our data corroborate the previous findings that isoflavones may
have protective effects and show that naturally occurring genistein
is a more potent inhibitory agent than the synthetic isoflavones
produced, which had been formulated specifically for their tyro-
sine kinase activity. Our data provide evidence that isoflavones can
reduce gastrointestinal cell proliferation and induce apoptosis. An
effect was observed in both non-transformed and cancer cells.Isoflavone effects on gut epithelial cells 1557
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Therefore, isoflavones may have a role to play in both protecting
normal tissues against tumour development and inhibiting estab-
lished tumour growth.
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